132 related articles for article (PubMed ID: 11814853)
1. Design, synthesis, and biological activity of novel factor Xa inhibitors: 4-aryloxy substituents of 2,6-diphenoxypyridines.
Ng HP; Buckman BO; Eagen KA; Guilford WJ; Kochanny MJ; Mohan R; Shaw KJ; Wu SC; Lentz D; Liang A; Trinh L; Ho E; Smith D; Subramanyam B; Vergona R; Walters J; White KA; Sullivan ME; Morrissey MM; Phillips GB
Bioorg Med Chem; 2002 Mar; 10(3):657-66. PubMed ID: 11814853
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.
Pinto DJ; Orwat MJ; Wang S; Fevig JM; Quan ML; Amparo E; Cacciola J; Rossi KA; Alexander RS; Smallwood AM; Luettgen JM; Liang L; Aungst BJ; Wright MR; Knabb RM; Wong PC; Wexler RR; Lam PY
J Med Chem; 2001 Feb; 44(4):566-78. PubMed ID: 11170646
[TBL] [Abstract][Full Text] [Related]
4. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.
Dudley DA; Bunker AM; Chi L; Cody WL; Holland DR; Ignasiak DP; Janiczek-Dolphin N; McClanahan TB; Mertz TE; Narasimhan LS; Rapundalo ST; Trautschold JA; Van Huis CA; Edmunds JJ
J Med Chem; 2000 Nov; 43(22):4063-70. PubMed ID: 11063603
[TBL] [Abstract][Full Text] [Related]
5. Nonbenzamidine tetrazole derivatives as factor Xa inhibitors.
Quan ML; Ellis CD; He MY; Liauw AY; Woerner FJ; Alexander RS; Knabb RM; Lam PY; Luettgen JM; Wong PC; Wright MR; Wexler RR
Bioorg Med Chem Lett; 2003 Feb; 13(3):369-73. PubMed ID: 12565931
[TBL] [Abstract][Full Text] [Related]
6. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.
Phillips GB; Buckman BO; Davey DD; Eagen KA; Guilford WJ; Hinchman J; Ho E; Koovakkat S; Liang A; Light DR; Mohan R; Ng HP; Post JM; Shaw KJ; Smith D; Subramanyam B; Sullivan ME; Trinh L; Vergona R; Walters J; White K; Whitlow M; Wu S; Xu W; Morrissey MM
J Med Chem; 1998 Sep; 41(19):3557-62. PubMed ID: 9733480
[No Abstract] [Full Text] [Related]
7. Design and synthesis of factor Xa inhibitors and their prodrugs.
Song Y; Clizbe L; Bhakta C; Teng W; Wong P; Huang B; Tran K; Sinha U; Park G; Reed A; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2003 Jan; 13(2):297-300. PubMed ID: 12482444
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groups.
Phillips G; Guilford WJ; Buckman BO; Davey DD; Eagen KA; Koovakkat S; Liang A; McCarrick M; Mohan R; Ng HP; Pinkerton M; Subramanyam B; Ho E; Trinh L; Whitlow M; Wu S; Xu W; Morrissey MM
J Med Chem; 2002 Jun; 45(12):2484-93. PubMed ID: 12036356
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of novel potent nonpeptide thrombin inhibitors.
Hauel NH; Nar H; Priepke H; Ries U; Stassen JM; Wienen W
J Med Chem; 2002 Apr; 45(9):1757-66. PubMed ID: 11960487
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitors.
Huang W; Naughton MA; Yang H; Su T; Dam S; Wong PW; Arfsten A; Edwards S; Sinha U; Hollenbach S; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2003 Feb; 13(4):723-8. PubMed ID: 12639567
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors.
Zhang P; Zuckett JF; Woolfrey J; Tran K; Huang B; Wong P; Sinha U; Park G; Reed A; Malinowski J; Hollenbach S; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2002 Jun; 12(12):1657-61. PubMed ID: 12039584
[TBL] [Abstract][Full Text] [Related]
12. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.
Adler M; Davey DD; Phillips GB; Kim SH; Jancarik J; Rumennik G; Light DR; Whitlow M
Biochemistry; 2000 Oct; 39(41):12534-42. PubMed ID: 11027132
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides.
Jia ZJ; Wu Y; Huang W; Goldman E; Zhang P; Woolfrey J; Wong P; Huang B; Sinha U; Park G; Reed A; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2002 Jun; 12(12):1651-5. PubMed ID: 12039583
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization, and structure-activity relationships of amidine-substituted (bis)benzylidene-cycloketone olefin isomers as potent and selective factor Xa inhibitors.
Guilford WJ; Shaw KJ; Dallas JL; Koovakkat S; Lee W; Liang A; Light DR; McCarrick MA; Whitlow M; Ye B; Morrissey MM
J Med Chem; 1999 Dec; 42(26):5415-25. PubMed ID: 10639283
[TBL] [Abstract][Full Text] [Related]
15. Solid-phase synthesis of N-substituted amidinophenoxy pyridines as factor XA inhibitors.
Mohan R; Yun W; Buckman BO; Liang A; Trinh L; Morrissey MM
Bioorg Med Chem Lett; 1998 Jul; 8(14):1877-82. PubMed ID: 9873451
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.
Hirayama F; Koshio H; Ishihara T; Watanuki S; Hachiya S; Kaizawa H; Kuramochi T; Katayama N; Kurihara H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2002 Aug; 10(8):2597-610. PubMed ID: 12057649
[TBL] [Abstract][Full Text] [Related]
17. Aminoisoquinolines: design and synthesis of an orally active benzamidine isostere for the inhibition of factor XA.
Choi-Sledeski YM; Becker MR; Green DM; Davis R; Ewing WR; Mason HJ; Ly C; Spada A; Liang G; Cheney D; Barton J; Chu V; Brown K; Colussi D; Bentley R; Leadley R; Dunwiddie C; Pauls HW
Bioorg Med Chem Lett; 1999 Sep; 9(17):2539-44. PubMed ID: 10498204
[TBL] [Abstract][Full Text] [Related]
18. Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.
Corte JR; Pinto DJP; Fang T; Osuna H; Yang W; Wang Y; Lai A; Clark CG; Sun JH; Rampulla R; Mathur A; Kaspady M; Neithnadka PR; Li YC; Rossi KA; Myers JE; Sheriff S; Lou Z; Harper TW; Huang C; Zheng JJ; Bozarth JM; Wu Y; Wong PC; Crain EJ; Seiffert DA; Luettgen JM; Lam PYS; Wexler RR; Ewing WR
J Med Chem; 2020 Jan; 63(2):784-803. PubMed ID: 31833761
[TBL] [Abstract][Full Text] [Related]
19. Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.
Quan ML; Han Q; Fevig JM; Lam PY; Bai S; Knabb RM; Luettgen JM; Wong PC; Wexler RR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1795-8. PubMed ID: 16434195
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological activity of non-amidine factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units.
Haginoya N; Kobayashi S; Komoriya S; Yoshino T; Nagata T; Hirokawa Y; Nagahara T
Bioorg Med Chem; 2004 Nov; 12(21):5579-86. PubMed ID: 15465335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
